Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In patients with atrial fibrillation (AF), anticoagulant therapy is effective in preventing thromboembolic events, but increases the risk of major bleeding. Impaired kidney function is known to contribute to the risk of bleeding; however, detailed evidence in Japan is limited. This study aimed to clarify the association between renal function and bleeding risk among AF patients receiving anticoagulation therapy, using large-scale real-world data of Japanese.
We conducted a retrospective cohort study using the JMDC Claims Database (Japan Medical Data Center, Tokyo, Japan). A total of 1,628 patients who were diagnosed with AF between January 2005 and June 2017, received anticoagulant therapy, and had available health checkup data were included. Estimated glomerular filtration rate (eGFR) was calculated using the Japanese Society of Nephrology equation, and renal function was categorized into three groups: eGFR ≥60, 45–59, and <45 mL/min/1.73m². The outcome was the occurrence of major bleeding, defined as a composite of intracranial hemorrhage, gastrointestinal bleeding and other bleeding events. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models.
During a mean follow-up period of 3.3 years, 58 major bleeding events occurred among the 1,628 patients receiving anticoagulants. The incidence rates of major bleeding (per 1,000 person-years) were 9.45 in the eGFR ≥60 group, 11.8 in the 45–59 group, and 31.4 in the <45 group, showing an increasing trend with declining renal function. After adjusting for age, sex, body mass index, smoking, alcohol consumption, regular exercise, hypertension, diabetes, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, and the use of antihypertensive and lipid-lowering medications, the association remained significant. Adjusted HRs (95% CI) were 1.46 (0.73–2.93) for the eGFR 45–59 group and 2.79 (1.13–6.87) for the <45 group, compared to the eGFR ≥60 group (p for trend = 0.027).
Among AF patients receiving anticoagulant therapy, declining renal function was associated with an increased risk of major bleeding. It may be important to regularly monitor and evaluate kidney function to properly manage bleeding risk among patients with AF receiving anticoagulation therapy.
